411 results on '"Boursier, Jerome"'
Search Results
2. A multisociety Delphi consensus statement on new fatty liver disease nomenclature
3. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
4. MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis
5. Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms
6. Food perception induces fast fragmentation of hepatic mitochondria
7. An international multidisciplinary consensus statement on MAFLD and the risk of CVD
8. Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population
9. Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL Study
10. A multisociety Delphi consensus statement on new fatty liver disease nomenclature
11. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
12. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
13. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol
14. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients
15. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
16. Associations between perfluoroalkyl substances and the severity of non-alcoholic fatty liver disease
17. A global research priority agenda to advance public health responses to fatty liver disease
18. Extracellular vesicles are carriers of adiponectin with insulin-sensitizing and anti-inflammatory properties
19. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
20. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study
21. Voies thérapeutiques dans l’hépatopathie stéatosique métabolique
22. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications
23. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
24. WED-227 Transient elastography performance for the diagnosis of liver fibrosis in MASLD is independent of steatosis level as determined by MRI proton density fat fraction in a prospective multicentrer study
25. OS-053 Screening candidates for therapeutic trials in MASH: choose the right non-invasive test for the diagnostic target considered
26. GS-004 Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
27. SAT-206 Improvements in MACK-3, a diagnostic test for active metabolic dysfunction-associated steatohepatitis, parallel response to lanifibranor therapy
28. THU-503 Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease (MASLD): multicenter study comparing patients with or without underlying cirrhosis
29. LBO-001 Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial
30. WED-224 Screening for liver fibrosis in tertiary care using automatic calculation of FIB4 in patients at-risk of diabetes
31. OS-060 Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)
32. Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study)
33. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
34. Reliability Criteria of Two-Dimensional Shear Wave Elastography: Analysis of 4277 Measurements in 788 Patients
35. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
36. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study
37. Quality Criteria for Liver Stiffness Measurement by Transient Elastography
38. Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement
39. LPS-enriched small extracellular vesicles from metabolic syndrome patients trigger endothelial dysfunction by activation of TLR4
40. Case-finding strategies in non-alcoholic fatty liver disease
41. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease
42. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment
43. Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis
44. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study
45. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database
46. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
47. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
48. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
49. Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD
50. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.